Estimating creatinine clearance for Malaysian critically ill patients with unstable kidney function and impact on dosage adjustment

Yen Ping Ng¹,², Angel Wei Ling Goh¹, Chee Ping Chong*¹

¹Discipline of Clinical Pharmacy, School of Pharmaceutical Sciences, Universiti Sains Malaysia (USM), 11800 Minden, Penang, Malaysia
²Clinical Pharmacy and Pharmacy Practice Unit, AIMST University, 08100 Bedong, Kedah, Malaysia

Article History:
Received on: 22 Dec 2019
Revised on: 02 Jan 2020
Accepted on: 15 Feb 2020

Keywords:
unstable kidney function, creatinine clearance, critically ill patients, dosage adjustment

ABSTRACT
It is an essential requirement to estimate glomerular filtration rate in dosing adjustment of drug treatment for critically ill patients with unstable kidney function. Previous studies showed that Cockcroft-Gault equation was not appropriate for the assessment of unstable kidney function. However, there is a lack of assessment on other equations specifically designed for fluctuating kidney functions. This study is aimed to evaluate the differences between estimated creatinine clearances by using Cockcroft-Gault, Jelliffe, Brater, and Chiou equations and the impact on dosing adjustment of renally excreted drugs for critically ill patients with unstable kidney function. A retrospective observational study was conducted among 103 patients with unstable kidney function who were admitted to intensive care unit of Taiping Hospital, Malaysia. Serum creatinine levels from day 1 to 7 of admission were collected. The median differences of estimated creatinine clearance based on the four different equations were analysed by Friedman-ANOVA test. The median estimated creatinine clearances when patients were having fluctuating kidney functions showed 35.69 ml/min (IQR: 22.57 – 53.97) by Cockcroft-Gault and 22.64 ml/min (IQR: 10.46 – 38.49) by Jelliffe equation, while Brater and Chiou equations showed 35.88 ml/min (IQR: 19.46 – 56.04) and 30.10 ml/min (IQR: 16.55 – 46.82) respectively. Jelliffe and Chiou equation showed a significant 36.56% and 15.66% lower estimated creatinine clearance respectively as compared to Cockcroft-Gault (p < 0.001). Meanwhile, there was no significant difference between Brater and Cockcroft-Gault equation. Jelliffe equation demonstrated the lowest estimated creatinine clearance value with a more intense dosage adjustment required for patients’ drug regimen involving renally excreted drugs. In conclusion, there were clinically significant variations in the estimated creatinine clearance from the different equations.

INTRODUCTION
Acute renal failure or more recently known as acute kidney injury is a common complication in hospitalized patients and is associated with high mortality rate [Mehta et al., 2004; Uchino et al., 2005]. The incidence of acute kidney injury is markedly higher in critically ill patients with fluctuating kidney function [Chertow et al., 2005; Mehta et al., 2004]. The decline in kidney function contributes to the accumulation of renally excreted drugs, leading to potential drug toxicity [Peyrière et al., 2001]. Besides, the
reduced kidney function may also cause an impairment in hepatic and intestinal drugs metabolism. Prominent changes in pharmacokinetics particularly protein bindings and serum amino acid levels may also be observed in patients with unstable kidney function. Consequently, the concentration of free drugs will increase concurrently with an altered volume of distribution and could possibly lead to drug toxicity (Blanco et al., 2019).

Several studies suggested that the Modification of Diet in Renal Disease (MDRD) and Cockcroft-Gault equations are both highly correlated with measured glomerular filtration rate (Golik and Lawrence, 2008; Nguyen et al., 2009). Nevertheless, the use of the MDRD equation often overestimates creatinine clearance, leading to errors in drug dosing compared with doses calculated by using Cockcroft-Gault equation (Hermsen et al., 2009; Wargo et al., 2006). For instance, a study involving 409 chronic kidney disease (CKD) stage 3 to 5 patients found that kidney function estimates using MDRD equation were approximately 13% to 26% higher than Cockcroft-Gault derived creatinine clearance estimates (Wargo et al., 2006). The Cockcroft-Gault equation is the most widely recognized method for drug dosage adjustment. However, it is not the most accurate equation to be used in acute kidney injury as the derivation of this equation involved only males with stable kidney function (Awdishu et al., 2018; Cockcroft and Gault, 1976).

Estimation of creatinine clearance has been a challenge in critical care due to the fluctuations in patients’ kidney function, creatinine production, and fluid balance (Jelliffe and Jelliffe, 1972). There was no consensus on the most appropriate equation to be applied in clinical practice. The 24-hour urine creatinine clearance is the standard. The commonly used Cockcroft-Gault equation is considered inaccurate as compared to the 24-hour urine creatinine clearance (Giles and Fitzmaurice, 2007). Nevertheless, the 24-hour urine creatinine clearance involves timed urine collections which are cumbersome to perform (Giles and Fitzmaurice, 2007). Inaccurate creatinine clearance estimation for dosing adjustment may lead to ineffective drug therapy or toxicity. Therefore, there is a need for careful individualization of drug dosage. The equations by Jelliffe (Jelliffe and Jelliffe, 1972; Brater, 1983) or Chiou (Chiou and Hsu, 1975) are options but these equations were not robustly tested and there was a debate on accuracy (Bouchard et al., 2010). These equations are better choices for unstable kidney functions since they involve the use of two consecutive serum creatinine values in the estimation of creatinine clearance. Meanwhile, Cockcroft-Gault equation uses only one serum creatinine value in the estimation and tends to overestimate and underestimate the glomerular filtration rate in patients with deteriorating and improving kidney functions respectively (Dager and Halilovic, 2014). A previous study revealed that estimated glomerular filtration rate computed using Jelliffe equation correlated best with urinary creatinine clearance as compared to the Cockcroft-Gault equation in critically ill patients with acute kidney injury (Bouchard et al., 2010). The Jelliffe and Cockcroft-Gault equations overestimated urinary creatinine clearance by 10% and 80% respectively (Bouchard et al., 2010). Therefore, the Jelliffe equation is more accurate in creatinine clearance estimation for patients with unstable kidney function as compared to the Cockcroft-Gault equation. Meanwhile, studies assessing the use of Brater and Chiou equations in the clinical setting and studies involving Asian population are limited.

A previous survey from the ACCP Nephrology and Critical Care Practice and Research Network showed approximately 95% of critical care pharmacists used Cockcroft-Gault equation to estimate creatinine clearance for dosage adjustment (Dowling et al., 2010). In Malaysia, estimating creatinine clearance using Cockcroft-Gault equation remained as the preference for most practicing clinical pharmacists and clinicians. The mortality in critical care could be partly contributed by the inappropriate drug dosing due to inaccurate prediction of patients’ kidney function. The critical care population is exceptionally vulnerable for which undershing of antibiotics will lead to poor response and mortality; while overdosing will lead to undesired side effects, permanent damages or even death secondary to multiple complications (Ali et al., 2019). Hence, clinicians and pharmacists should consider using more reliable alternative methods in guiding drug dosing for patients with unstable kidney function (Jelliffe and Jelliffe, 1972).

There is a need for conducting a study to conclude an appropriate equation for estimating kidney function in critically ill patients. This study aimed to investigate the differences between estimated creatinine clearances with Cockcroft-Gault, Jelliffe, Chiou, and Brater equations for critically ill patients with unstable kidney function. This study finding will provide an insight for dosage adjustment of renally excreted drugs in critical care.

**MATERIALS AND METHODS**

This was a single-centred, retrospective study involving a total of 103 patients admitted to
Table 1: Equations for estimating of creatinine clearance (CrCl) in adults with unstable kidney function

| Equation 1: Cockcroft-Gault (ml/min) Male | \( CrCl \) (male) = \( \frac{(140-\text{age}) \times Wt}{72 \times Scr} \) |
|------------------------------------------|---------------------------------------------------------------|
| Equation 2: Jelliffe (ml/min per 1.73m²) Male | \( E_{\text{males}} = Wt \times [29.3 - 0.203(\text{age})] \) |
| Correct Ess for nonrenal creatinine excretion in chronic kidney disease: | \( Esscorr = Ess \times [1.035 - 0.0337(Scr)] \) |
| Scr = If serum creatinine values are rising, enter the most recent Scr. If Scr values are declining enter the average value between the two Scr values. | \( E = Esscorr - \frac{\text{Time in days between Scr1 and Scr2}}{[4 \times Wt \times (Scr2 - Scr1)]} \) |
| Scr2 = latest serum creatinine; Scr1 = earlier serum creatinine | \( Ess = \frac{E}{Scr} \times \frac{\text{Time in days between Scr1 and Scr2}}{[4 \times Wt \times (Scr2 - Scr1)]} \) |
| Correct Ess for nonrenal creatinine excretion in chronic kidney disease: | \( Esscorr = Ess \times [1.035 - 0.0337(Scr)] \) |
| Scr = If serum creatinine values are rising, enter the most recent Scr. If Scr values are declining enter the average value between the two Scr values. | \( E = Esscorr - \frac{\text{Time in days between Scr1 and Scr2}}{[4 \times Wt \times (Scr2 - Scr1)]} \) |
| Scorr = Correct Ess for nonrenal creatinine excretion in chronic kidney disease: | \( Esscorr = Ess \times [1.035 - 0.0337(Scr)] \) |
| Scr = If serum creatinine values are rising, enter the most recent Scr. If Scr values are declining enter the average value between the two Scr values. | \( E = Esscorr - \frac{\text{Time in days between Scr1 and Scr2}}{[4 \times Wt \times (Scr2 - Scr1)]} \) |

| Equation 3: Brater (ml/min per 70kg) Male | \( CrCl = \frac{[293 - 2.03(\text{age})] \times [1.035 - 0.01685(Scr + Scr2)]}{(Scr + Scr2) \times \text{time in days between Scr1 and Scr2}} \) |
|------------------------------------------|---------------------------------------------------------------|
| Convert \( CrCl \) (ml/min/70kg) to \( CrCl \) (ml/min) | \( \frac{CrCl \times Wt \times (Scr + Scr2)}{2} \) |

| Equation 4: Chou (ml/min) Male | \( CrCl = 0.6 \times L/kg \times Wt \) |
|------------------------------------------|---------------------------------------------------------------|
| Convert \( CrCl \) (ml/min/70kg) to \( CrCl \) (ml/min) | \( \frac{CrCl \times Wt \times [28 - 0.2(\text{age})]}{14.4(Scr + Scr2) \times Vd} \) |

| Female | \( CrCl \) (female) = \( \frac{(140-\text{age}) \times Wt}{72 \times Scr} \) \times 0.85 |
|------------------------------------------|---------------------------------------------------------------|
| Equation 2: Jelliffe (ml/min per 1.73m²) Female | \( E_{\text{females}} = Wt \times [25.1 - 0.175(\text{age})] \) |
| Correct Ess for nonrenal creatinine excretion in chronic kidney disease: | \( Esscorr = Ess \times [1.035 - 0.0337(Scr)] \) |
| Scr = If serum creatinine values are rising, enter the most recent Scr. If Scr values are declining enter the average value between the two Scr values. | \( E = Esscorr - \frac{\text{Time in days between Scr1 and Scr2}}{[4 \times Wt \times (Scr2 - Scr1)]} \) |
| Scorr = Correct Ess for nonrenal creatinine excretion in chronic kidney disease: | \( Esscorr = Ess \times [1.035 - 0.0337(Scr)] \) |
| Scr = If serum creatinine values are rising, enter the most recent Scr. If Scr values are declining enter the average value between the two Scr values. | \( E = Esscorr - \frac{\text{Time in days between Scr1 and Scr2}}{[4 \times Wt \times (Scr2 - Scr1)]} \) |

| Equation 3: Brater (ml/min per 70kg) Female | \( CrCl = \frac{[22.4 - 0.16(\text{age})](Scr + Scr2)}{14.4(Scr1 + Scr2) \times Vd} \) |
|------------------------------------------|---------------------------------------------------------------|
| Convert \( CrCl \) (ml/min/70kg) to \( CrCl \) (ml/min) | \( \frac{CrCl \times Wt \times (Scr1 + Scr2)}{2} \) |

| Female | \( CrCl = \frac{Volume \text{ distribution of creatinine,}}{Vd} = 0.6 \times L/kg \times Wt \) |
|------------------------------------------|---------------------------------------------------------------|
| Convert \( CrCl \) (ml/min/70kg) to \( CrCl \) (ml/min) | \( \frac{CrCl \times Wt \times [22.4 - 0.16(\text{age})]}{14.4(Scr1 + Scr2) \times Vd} \) |

| Equation 3: Brater (ml/min per 70kg) Female | \( CrCl = \) Male value \times 0.86 |
|------------------------------------------|---------------------------------------------------------------|
| Convert \( CrCl \) (ml/min) to \( CrCl \) (ml/min/70kg) | \( \frac{CrCl \times Wt \times (Scr1 + Scr2)}{2} \) |

| Female | \( CrCl = \) Male value \times 0.86 |
|------------------------------------------|---------------------------------------------------------------|
| Convert \( CrCl \) (ml/min/70kg) to \( CrCl \) (ml/min) | \( \frac{CrCl \times Wt \times (Scr1 + Scr2)}{2} \) |

CrCl = Creatinine clearance; E = Creatinine excretion; Ess = Steady state creatinine excretion; Esscorr = Corrected steady state creatinine excretion; Scr = Serum creatinine value; Scr1 = First serum creatinine value; Scr2 = Second serum creatinine value; Vd = Volume of distribution; Wt = Body weight (use ideal bodyweight, IBW if weight > 30% above IBW)
Table 2: Baseline characteristics of the patients

| Characteristics                              | n (%)  |
|----------------------------------------------|--------|
| **Gender**                                   |        |
| Female                                       | 53 (51.5) |
| Male                                         | 50 (48.5) |
| **Ethnic background**                        |        |
| Malay                                        | 73 (70.9) |
| Indian                                       | 17 (16.5) |
| Chinese                                      | 12 (11.7) |
| Others                                       | 1 (1.0) |
| **Reasons for ICU admission**                |        |
| Infectious Disease                           | 75 (72.8) |
| Surgery                                      | 14 (13.6) |
| Respiratory diseases                         | 6 (5.8) |
| CVD                                          | 6 (5.8) |
| CVA                                          | 2 (1.9) |
| **Medical history**                          |        |
| Diabetes & hypertension                      | 15 (14.6) |
| Diabetes                                     | 11 (10.7) |
| Diabetes, hypertension & dyslipidemia        | 9 (8.7) |
| CKD, diabetes & hypertension                | 8 (7.8) |
| Hypertension                                 | 6 (5.8) |
| Dyslipidemia & hypertension                  | 5 (4.9) |
| CVD, diabetes & hypertension                | 5 (4.9) |
| Diabetes, hypertension, dyslipidemia & CKD   | 4 (3.9) |
| CVD                                          | 4 (3.9) |
| Hyperlipidemia                               | 2 (1.9) |
| Liver disease                                | 1 (1.0) |
| CKD                                          | 1 (1.0) |
| COPD                                         | 1 (1.0) |
| No known co-morbidity                        | 31 (30.1) |
| **Medication history**                       |        |
| ACEi/ARB & platelet aggregation inhibitor    | 21 (20.4) |
| ACEi/ARB                                     | 18 (17.5) |
| ACEi/ARB & platelet aggregation inhibitor &  | 5 (4.9) |
| diuretic                                     |        |
| Platelet aggregation inhibitor               | 3 (2.9) |
| Diuretic                                     | 2 (1.9) |
| ACEi/ARB & diuretic                          | 1 (1.0) |
| Not on any medication                        | 53 (51.5) |

ACEi = Angiotensin converting enzyme inhibitor; ARB = Angiotensin II receptor antagonist; CVA = Cerebrovascular accident; CVD = Cardiovascular disease; CKD = Chronic kidney disease; COPD = Chronic obstructive pulmonary disease
Table 3: Comparison of estimated creatinine clearance (CrCl) based on Cockcroft-Gault, Jelliffe, Brater and Chiou equations

| Equation to estimate CrCl | Median CrCl (ml/min) | Friedman-ANOVA test statistic, $\chi^2$(df) & p value | Post-hoc analysis (Wilcoxon signed rank test) |
|---------------------------|----------------------|--------------------------------------------------------|---------------------------------------------|
| **Day 1 (Baseline) (N = 103)** | | | |
| Cockcroft-Gault | 55.80 (IQR: 37.41-84.90) | $\chi^2(3) = 215.82$; p < 0.001 | CG vs J ($Z = -8.797$, p < 0.001) |
| Jelliffe | 28.39 (IQR: 17.51-50.60) | | CG vs B ($Z = -7.080$, p < 0.001) |
| Brater | 40.69 (IQR: 25.48-61.38) | | CG vs C ($Z = -8.521$, p < 0.001) |
| Chiou | 36.70 (IQR: 27.78-59.79) | | J vs B ($Z = -8.636$, p < 0.001) |
| | | | J vs C ($Z = -8.299$, p < 0.001) |
| | | | B vs C ($Z = -0.405$, p = 0.686) |
| **Deteriorating trend** (N = 390) | | | |
| Cockcroft-Gault | 34.03 (IQR: 21.74 – 52.33) | $\chi^2(3) = 684.72$; p < 0.001 | CG vs J ($Z = -16.993$, p < 0.001) |
| Jelliffe | 19.99 (IQR: 10.19 – 35.64) | | CG vs B ($Z = -4.978$, p < 0.001) |
| Brater | 32.13 (IQR: 17.63 – 47.82) | | CG vs C ($Z = -14.690$, p < 0.001) |
| Chiou | 27.79 (IQR: 15.69 – 41.64) | | J vs B ($Z = -16.508$, p < 0.001) |
| | | | J vs C ($Z = -14.805$, p < 0.001) |
| | | | B vs C ($Z = -8.935$, p < 0.001) |
| **Rapid deteriorating trend** (N = 38) | | | |
| Cockcroft-Gault | 26.13 (IQR: 13.44 – 39.23) | $\chi^2(3) = 63.32$; p < 0.001 | CG vs J ($Z = -5.272$, p < 0.001) |
| Jelliffe | 16.99 (IQR: 4.68 – 29.49) | | CG vs B ($Z = -1.385$, p = 0.166) |
| Brater | 27.77 (IQR: 17.05 – 44.53) | | CG vs C ($Z = -3.879$, p < 0.001) |
| Chiou | 21.75 (IQR: 10.22 – 34.79) | | J vs B ($Z = -5.098$, p < 0.001) |
| | | | J vs C ($Z = -4.198$, p < 0.001) |
| | | | B vs C ($Z = -4.546$, p < 0.001) |
| **Improving trend** (N = 171) | | | |
| Cockcroft-Gault | 39.39 (IQR: 26.87 – 57.09) | $\chi^2(3) = 302.78$; p < 0.001 | CG vs J ($Z = -10.440$, p < 0.001) |
| Jelliffe | 29.43 (IQR: 12.70 – 50.16) | | CG vs B ($Z = -6.524$, p < 0.001) |

Continued on next page
Table 3 continued

| Method          | Creatinine Clearance | Z-Score | p-Value |
|-----------------|----------------------|---------|---------|
| Brater          | 49.39 (IQR: 29.11 – 68.76) | -5.241 | <0.001 |
| Chiou           | 37.59 (IQR: 22.88 – 56.16) | -11.152| <0.001 |
|                 | J vs B (Z = -11.152, p < 0.001) |         |         |
|                 | J vs C (Z = -9.821, p < 0.001) |         |         |
|                 | B vs C (Z = -10.343, p < 0.001) |         |         |
| **Rapid improving trend** |                      |       |         |
| **(N = 43)**   |                      |       |         |
| Cockcroft-Gault | 51.19 (IQR: 35.22 – 84.79) | -4.552| <0.001 |
| Jelliffe        | 37.98 (IQR: 24.67 – 70.50) | -2.946| 0.003  |
| Brater          | 56.60 (IQR: 41.90 – 95.60) | -2.258| 0.024  |
| Chiou           | 45.15 (IQR: 32.60 – 76.05) | -5.567| <0.001 |
|                 | J vs B (Z = -5.567, p < 0.001) |         |         |
|                 | J vs C (Z = -4.051, p < 0.001) |         |         |
|                 | B vs C (Z = -4.951, p < 0.001) |         |         |
| **Overall trend** |                      |       |         |
| **(N = 561)**  |                      |       |         |
| Cockcroft-Gault | 35.69 (IQR: 22.57 – 53.97) | -19.961| <0.001 |
| Jelliffe        | 22.64 (IQR: 10.46 – 38.49) | -0.425| 0.671  |
| Brater          | 35.88 (IQR: 19.46 – 56.04) | -15.494| <0.001 |
| Chiou           | 30.10 (IQR: 16.55 – 46.82) | -19.921| <0.001 |
|                 | J vs B (Z = -19.921, p < 0.001) |         |         |
|                 | J vs C (Z = -17.747, p < 0.001) |         |         |
|                 | B vs C (Z = -13.791, p < 0.001) |         |         |

*Creatinine clearance in deteriorating trend (serum creatinine at increasing trend). *Creatinine clearance for patients with more than 50% increase in serum creatinine within 24 hours. *Creatinine clearance in improving trend (serum creatinine at decreasing trend). *Creatinine clearance for patients with more than 50% decreased in serum creatinine within 24 hours.

© International Journal of Research in Pharmaceutical Sciences
| Patient No. | Drug Regimen (Name, dose, frequency) | Calculated CrCl (ml/min) based on different method | Dose adjustment requirement |
|-------------|-------------------------------------|--------------------------------------------------|----------------------------|
|             |                                     | C-G | J | B | C                          | C-G | J | B | C |
| 1.          | IV Tazosin 4.5 g TDS                | 32.69 | 8.85 | 13.60 | 18.28 | ✓ | ✓* | ✓* | ✓* |
| 2.          | IV Tazosin 4.5 g QID                | 22.57 | 11.41 | 12.46 | 16.12 | ✓ | ✓* | ✓* | ✓* |
| 3.          | IV Imipenem 500 mg QID              | 31.14 | 18.07 | 44.64 | 30.20 | ✓* | ✓* | ✓ | ✓* |
| 4.          | IV Meropenem 1g TDS                 | 24.01 | 11.36 | 29.11 | 21.57 | ✓* | ✓* | ✓ | ✓* |
| 5.          | IV T. Digoxin 0.25 mg OD            | 14.23 | 7.77 | 8.77 | 10.14 | ✓ | ✓* | ✓* | ✓ |
| 6.          | IV Meropenem 500 mg BD              | 17.71 | 3.20 | 2.91 | 10.54 | ✓ | ✓* | ✓* | ✓ |
| 7.          | IV Imipenem 500 mg QID              | 22.06 | 7.80 | 25.55 | 20.10 | ✓ | ✓* | ✓ | ✓* |
| 8.          | IV Imipenem 500 mg QID              | 53.67 | 38.72 | 51.85 | 44.33 | ✓ | ✓* | ✓ | ✓ |
| 9.          | IV Imipenem 500 mg QID              | 31.80 | 14.10 | 34.45 | 28.94 | ✓ | ✓* | ✓ | ✓ |
| 10.         | IV Imipenem 1 g QID                 | 44.10 | 34.18 | 59.25 | 43.70 | ✓ | ✓* | ✓ | ✓ |
| 11.         | IV Meropenem 1 g TDS                | 36.78 | 23.93 | 47.55 | 36.97 | ✓ | ✓* | ✓ | ✓ |
| 12.         | IV Meropenem 1 g TDS                | 21.13 | 8.60 | 26.01 | 18.86 | ✓ | ✓* | ✓ | ✓ |
| 13.         | IV Meropenem 1 g TDS                | 39.54 | 25.33 | 46.58 | 38.25 | ✓ | ✓* | ✓ | ✓ |
| 14.         | IV Meropenem 2 g TDS                | 28.20 | 15.69 | 37.14 | 26.86 | ✓ | ✓* | ✓ | ✓ |

*Continued on next page*
|   | Drug          | Dose | Route | CI  | J  | B  | C  | D  |
|---|--------------|------|-------|-----|----|----|----|----|
| 15| IV Imipenem  | 500 mg | TDS   | 23.29 | ✓  | ✓  | ✓  | ✓  |
| 16| IV Meropenem | 1 g BD |       | 28.44 | 18.22 | 22.79 | 21.12 | X  | ✓  | ✓  | ✓  |
| 17| IV Meropenem | 1 g TDS |       | 24.08 | 16.66 | 51.04 | 29.62 | ✓  | ✓  | ✓  | ✓  |
| 18| IV Tazosin   | 4.5 g | QID   | 30.86 | 22.31 | 51.43 | 32.79 | ✓  | ✓  | X  | ✓  |
| 19| IV Meropenem | 1 g TDS |       | 42.34 | 32.62 | 57.62 | 42.70 | ✓  | ✓  | X  | ✓  |
| 20| IV Meropenem | 1 g TDS |       | 44.34 | 31.80 | 53.91 | 43.84 | ✓  | ✓  | X  | ✓  |
| 21| IV Tazosin   | 2.25 g | TDS   | 44.74 | 31.42 | 53.83 | 40.76 | X  | ✓  | X  | X  |
| 22| IV Cefepime  | 2 g   | BD    | 33.60 | 23.34 | 49.92 | 35.01 | X  | ✓  | X  | X  |
| 23| IV Meropenem | 1 g BD |       | 38.69 | 22.89 | 30.37 | 28.41 | X  | ✓  | X  | X  |
| 24| IV Meropenem | 1 g BD |       | 31.20 | 15.96 | 35.88 | 27.76 | X  | ✓  | X  | X  |
| 25| IV Sulperazone | 2 g | QID   | 36.04 | 19.14 | 40.60 | 33.49 | ✓  | ✓  | X  | X  |

C-G = Cockcroft-Gault equation; J = Jelliffe equation; B = Brater equation; C = Chiou equation; ✓ = Dosage adjustment required; *= Dosage adjustment required at higher intensity; X = No dosage adjustment required
intensive care unit (ICU) of Taiping Hospital, state of Perak, Malaysia from year 2010 to 2012. This study was granted ethics approval by the Medical Research & Ethics Committee, Malaysia on 20th May 2013 (NMRR-12-1299-14330).

The inclusion criteria were adult ICU patients (older than 18 years) with documented acute kidney injury or unstable kidney function. Acute kidney injury is defined as an acute decrease in kidney function (Glomerular filtration rate) over a period of hours, days, or even weeks, associated with an accumulation of waste products and (usually) volume. Unstable kidney function is defined as an increase in serum creatinine of 0.5 mg/dl (44.2 μmol/L) or a decrease of 25% or greater in the glomerular filtration rate of patients with a previously normal kidney function; or an increase of 1.0 mg/dl or greater in patients with chronic kidney disease within 48 hours (Dager and Halilovic, 2014). It is also defined based on urine output, which is less than 0.5 ml/kg/hour for at least 6 hours (Dager and Halilovic, 2014). The patients with incomplete data, documented kidney transplantation, pregnancy, previous history of renal replacement therapy, receiving dialysis from the ICU, serum creatinine more than 400 μmol/L, acute kidney injury from urinary tract obstruction, oliguric or anuric, seizure disorders, hypovolemic responsive to fluid, and psoriasis were excluded.

Patients’ demographic, ICU admission reasons, past medical history, past medication history and drug treatment in the ICU were recorded. Besides, Simplified Acute Physiology Score II (SAPS II) score, laboratory data and urine output were also recorded. The serum creatinine as a key biomarker was collected from day 1 to day 7. This was owing to serum creatinine needs a week to stabilize when there is a change in kidney function as shown by a previous study (Bouchard et al., 2010).

The creatinine clearances of the patients were subsequently calculated by using Cockcroft-Gault, Jelliffe, Chiou and Brater equations (Table 1). The creatinine clearance units for Jelliffe (ml/min/1.73m²) and Brater (ml/min/70kg) were converted to ml/min. The conversion was conducted to standardise the values of estimated creatinine clearance to the same units for comparisons. Besides, ideal body weight (IBW) were used in this study for the creatinine clearance estimation as documented by the hospital dieticians in the patients’ case notes (at the nutritional referral form). The patients’ actual body weights (ABW) were untraceable in the case notes.

Statistical analysis was performed by using SPSS® version 20.0 software. Descriptive statistics such as mean and standard deviation were used to summarise the continuous variables which were normally distributed. Median and interquartile range (IQR) were used if the data was not normally distributed. Besides, the differences between calculated creatinine clearance based on Cockcroft-Gault, Jelliffe, Brater, and Chiou equations were analysed using Friedman-ANOVA test. Follow-up post-hoc analysis by using Wilcoxon Signed-Rank test was conducted to evaluate comparison between pairs of the calculated creatinine clearance. Statistically significant was set at a p value of less than 0.05.

The patients’ drug regimen involving renally excreted drugs were evaluated for the need of dosage adjustment according to the creatinine clearance estimated by the four equations. The drug dosages were evaluated by using the IBM Micromedex® (an evidence-based, multi-database drug search engine).

RESULTS AND DISCUSSION

A total of 103 patients who fulfilled the inclusion criteria were selected from a pool of 1500 patients through convenient sampling. Majority (51.5%) of the patients were female. All the patients were from Asian population with most of them were Malays (70.9%) (Table 2). The patients had mean age of 57.91 ± 16.04 years old with mean body weight of 61.79 ± 9.55 kg and median height of 163.00 cm (IQR: 156.00 – 170.00 cm). The mean body weight for male patients was 67.43 ± 8.80 kg with a median height of 169.50 cm (IQR: 166.00 – 170.00 cm). Whereas, the mean weight for female patients was 56.47 ± 6.82 kg with a median height of 156.00 cm (IQR: 154.00 – 160.00 cm).

The most common complication that led to ICU admission was infectious disease (72.8%) either in the form of septicemia or sepsis. Approximately 51.5% of the studied patients had no medication history or with no history of taking chronically any renal toxic medications. Meanwhile, 20.4% of the patients were taking both angiotensin-converting enzyme inhibitor (ACEi) or angiotensin receptor blocker (ARB) and a platelet aggregation inhibitor (aspirin, aspirin plus glycerine or clopidogrel). Patients who were taking ACEi or ARB prior to admission was documented as much as 17.5% (Table 2). The mean SAPS II score of the patients was 46.31 ± 18.96 which carries a meaning of 50% mortality rate. The studied patients had a median serum creatinine at baseline of 99.00 (IQR: 70.80 – 137.00) μmol/L and a median blood urea nitrogen (BUN) level of 7.10 (IQR: 4.40 – 10.10) mmol/L.
Both baseline serum creatinine and BUN were at the higher end of normal range.

The comparison of creatinine clearance determined by four different methods was made for day 1 or at baseline when patients were still having stable kidney functions. The median creatinine clearance for Cockcroft-Gault, Jelliffe, Brater and Chiou equations were significantly different between each other based on post hoc analysis except for the Brater and Chiou pair. Using Cockcroft-Gault equation as standard, the creatinine clearance calculated by Jelliffe, Brater and Chiou equations were 49.12%, 27.08%, and 34.23% lower as compared to Cockcroft-Gault respectively. When the creatinine clearance was in a deteriorating trend (serum creatinine at increasing trend), with a total of 390 sets of serum creatinine measurements, significant differences (post hoc analysis) were found between all the equations. The magnitude of differences when comparing Jelliffe, Brater and Chiou to Cockcroft-Gault were 41.26%, 5.58% and 18.34% lower respectively (Table 3).

A subgroup analysis was performed on 38 sets of serum creatinine measurements with most rapid deteriorating kidney functions (more than 50% increase in serum creatinine within 24 hours). The Brater equation showed the highest estimated creatinine clearance, followed by Cockcroft-Gault, Chiou and Jelliffe. The median calculated creatinine clearances by Brater was 6.28% higher, while Jelliffe and Chiou were 34.98% and 16.76% lower respectively when compared to the Cockcroft-Gault equation. There were statistically significant differences among all pairs comparison except for the Cockcroft-Gault and Brater pair (Table 3).

A total of 171 sets of serum creatinine measurements which showed recovery of kidney function with an improving trend (decreasing trend in serum creatinine) were analysed. The Brater equation estimated the highest creatinine clearance. The calculated creatinine clearance by Jelliffe was 25.29% lower, Brater was 25.39% higher and Chiou was 4.57% lower as compared to Cockcroft-Gault. Post hoc analysis showed statistically significant difference in all pair’s comparison. A total of 43 sets of serum creatinine measurements with most rapid improving kidney functions (more than 50% decrease in serum creatinine within 24 hours) were identified. The estimated creatinine clearance by Brater equation was again higher than the other equations. The estimated creatinine clearances by Chiou and Jelliffe equations were 11.80% and 25.81% lower respectively when compared to Cockcroft-Gault. Meanwhile, the Brater estimated creatinine clearance was 10.57% higher than Cockcroft-Gault. Statistically significant differences were found among all the pairs comparison. Considering the overall trend of estimated creatinine clearance from all four equations with a total of 561 sets of measurements, significant difference was found between all pair’s comparisons except for the Cockcroft-Gault and Brater pair. Jelliffe and Chiou estimated the creatinine clearance lower than Cockcroft-Gault by 36.56% and 15.66% respectively. Whereas, Brater estimated creatinine clearance were slightly higher (0.53%) than Cockcroft-Gault (Table 3).

Patients’ drug regimen involving renally excreted drugs with distinct dosage adjustment recommendations according to the four equations were illustrated in Table 4. The estimated creatinine clearance using all four equations were also examined if dosage adjustment was required for patients’ different drug regimen. Jelliffe equation estimated the lowest creatinine clearance, hence it required dosage adjustment for all the 25 selected cases. Out of the 25 cases, 15 cases required the dose to be adjusted to a greater intensity as compared to the other equations. Meanwhile, Brater equation estimated creatinine clearance were mostly the highest, thus it only showed 16 cases needed dosage adjustment. Cockcroft-Gault and Chiou showed 19 and 20 cases needed dosage adjustment respectively. There was a case (case number 16) that required dose adjustment according to Jelliffe, Chiou and Brater equations but not by the Cockcroft-Gault equation. Meanwhile, there were four cases (case number 17-20) that required dosage adjustments by Cockcroft-Gault, Jelliffe and Chiou equations but not by the Brater equation. Besides, a total of five cases (case number 21-25) showed only dosage adjustments required by Jelliffe equation and not with the other three equations (Table 4).

This was among the first study comparing the differences among the estimated creatinine clearances calculated by Cockcroft-Gault, Jelliffe, Brater and Chiou equations for critically ill patients who developed acute kidney injury during the ICU stay that involved Asian population in Malaysia. Acute kidney injury is one of the most serious adverse events that can develop in ICU patients which may lead to a higher mortality rate (Chertow et al., 1998). Accurate estimation of kidney function is required to optimize drug administration. Despite being the gold standard for glomerular filtration rate estimation, inulin clearance is however very difficult and impractical for daily clinical use. This is because a constant intravenous infusion is needed to maintain a consistent level of inulin for its clearance mea-
surrent (Langlois, 2008). Besides, insulin is expensive for daily routine use. Hence, the most common way for accurate measurement of kidney function is 24 hours urine collection (Nguyen et al., 2009). However, this method might lead to inaccuracy secondary to urine collection error or anuria when patients were critically ill (Awidishu et al., 2018).

Several equations such as Cockcroft-Gault and MDRD have been developed for rapid estimation of patients’ kidney function (Golik and Lawrence, 2008; Nguyen et al., 2009). Cockcroft-Gault and MDRD use serum creatinine and other characteristics to provide an estimate of kidney function. Nevertheless, patients who are critically ill have fluctuating serum creatinine and kidney functions. Besides, there are certain patients’ characteristics which influence the creatinine production. For instance, severe liver disease, altered muscle mass or disposition secondary to unstable kidney function may render the creatinine-based equations inaccurate (Nyman et al., 2011). Poorer kidney function caused the creatinine clearance to overestimate the glomerular filtration rate due to the additional creatinine cleared by tubular secretion (Hermsen et al., 2009; Wargo et al., 2006). Both Cockcroft-Gault and MDRD equations require stable kidney function and serum creatinine concentration for glomerular filtration rate estimation. These two equations for creatinine clearance estimation may overestimate the kidney function in critically ill acute kidney injury patients based on the results from a previous study (Bouchard et al., 2010).

The estimation of creatinine clearance would be affected if patients were taking drugs that were affecting creatinine secretion through inhibition of active tubular secretion of creatinine (Zaltzman et al., 1996). For instance, drugs such as cimetidine, trimethoprim or probenecid would result in falsely low estimates of creatinine clearance when serum creatinine is solely used in the creatinine clearance estimation (Israni and Kasiske, 2007). In this study, none of the studied patients were prescribed with the above-mentioned drugs. However, 20.4% of the studied patients in this study were taking drugs that might worsen the kidney function, namely ACE inhibitors, ARB, diuretics and platelet aggregation inhibitor. However, the use of these drugs would not affect the creatinine secretion and the subsequent estimation of creatinine clearance.

The estimation of creatinine clearance also depends on the production of creatinine. Long term bedridden critically ill patients will experience muscular dystrophy, thus having low muscle mass. Creatinine is produced from the metabolism of muscle. Hence, lesser creatinine will be produced with low muscle mass, leading to low serum creatinine level. Creatinine clearance will be overestimated particularly by the Cockcroft-Gault equation due to the inverse proportional relationship between serum creatinine and creatinine clearance (O’Connell et al., 1992; Smythe et al., 1994). This was reflected in the present study findings whereby the estimated creatinine clearance by the Cockcroft-Gault equation was generally higher than the Jelliffe and Chiou equations. The Jelliffe and Chiou equations were affected to a lesser extent by the low muscle mass in ICU patients since these equations involved the changes of serum creatinine between two consecutive days and not solely depending on one serum creatinine value. Additionally, the nonrenal creatinine excretion is corrected in both the Jelliffe and Chiou equations (Chiu and Hsu, 1975; Jelliffe and Jelliffe, 1972). Although the Brater equation involved the use of two consecutive serum creatinine values, the nonrenal creatinine excretion is not corrected (Brater, 1983). This could be the reason for higher estimated creatinine clearance value by the Brater equation as compared to Jelliffe and Chiou equations.

A previous study conducted by Bouchard et al. which compared the estimated glomerular filtration rate calculated by Cockcroft-Gault and Jelliffe equations found that the estimation by Cockcroft-Gault equation was 49% higher than Jelliffe equation in acute kidney injury (Bouchard et al., 2010). Besides, glomerular filtration rate estimation by Jelliffe equation demonstrated a small deviation from urinary creatinine clearance as compared to Cockcroft-Gault (Bouchard et al., 2010). The present study also showed an overall trend of huge difference between Cockcroft-Gault and Jelliffe for the estimation of creatinine clearance. The Cockcroft-Gault estimated creatinine clearance was higher than Jelliffe by 36.6%. However, Brater and Chiou equations were not included in the Bouchard et al. study (Bouchard et al., 2010). Thus, the comparisons of estimated creatinine clearance using Cockcroft-Gault, Jelliffe, Brater and Chiou equations in this study will complement the results of Bouchard et al. study. As Brater and Cockcroft-Gault did not show significant difference in the estimated creatinine clearance, while only a small difference (15.7%) was observed between Chiou and Cockcroft-Gault equations, Jelliffe would be the most appropriate equation for unstable kidney function. However, there were differences in the demographic characteristics between the Bouchard et al. and this study. The Bouchard et al. study had only 2.8% of patients from Asian population and the mean base-
line body weight (81.9 + 19.7 kg) was higher as compared to the present studied patients due to the greater body sizes of Caucasians. These differences might have contributed to the deviation between the difference of Jelliffe and Cockcroft-Gault estimated creatinine clearance between these two studies.

During the acute kidney injury, the kidney function will initially in the deteriorating phase. After a few days, the kidney function will start to recover. The kidney is considered deteriorating if the serum creatinine level is increasing and vice versa (Dager and Halilovic, 2014). It is essential to specifically assess the most accurate equation to be used for the estimation of creatinine clearance in both deteriorating and recovering phases of acute kidney injury. The Jelliffe equation showed the lowest estimated creatinine clearance among the four equations and demonstrated the highest deviation from the Cockcroft-Gault equation for both deteriorating and improving trends of kidney function. This was consistent with the overall trend that Jelliffe estimated the lowest creatinine clearance. Hence, Jelliffe equation would tend to have a more intense dosage adjustment as compared to the other three equations. Brater, Chiou and Cockcroft-Gault equations estimated higher creatinine clearance. Thus, there would be a higher tendency of overdosing if the three equations were used, leading to dose dependent adverse effects or Type A reactions (Pirmohamed and Park, 2003).

Strength and Limitations

As this is a retrospective study, it relied on the written record accuracy. Some important data might be missing, thus leading to the exclusion of many potential patients. This study was also limited with the absence of the use of 24-hour urine creatinine clearance and Modified Jelliffe equation for the assessment of unstable kidney function. Besides, this retrospectively designed study could not assess the clinical outcomes of dosage adjustment based on different equations. Hence, there is a need for future prospective studies to compare more equations used to assess unstable kidney functions including the use of Modified Jelliffe equation and the gold standard urine creatinine collection method. The evaluation of clinical outcomes on dosage adjustments based on various unstable kidney function equations should also be carried out in future studies.

CONCLUSIONS

Jelliffe equation might be a more suitable equation to assess patients with unstable kidney functions. The Brater and Chiou equations might lead to higher doses of renally excreted drugs due to higher estimated creatinine clearances.

ACKNOWLEDGEMENTS

The authors thank the Director General of Health Malaysia for permission to publish this paper.

Declaration Of Conflicting Interests

The authors declared no potential conflicts of interest with respect to the research, authorship, and/or publication of this article.

Funding Support

The authors received no financial support for the research, authorship, and/or publication of this article.

REFERENCES

Ali, M., Naureen, H., Tariq, M. H., Farrukh, M. J., Usman, A., Khattak, S., Ahsan, H. 2019. Rational use of antibiotics in an intensive care unit: a retrospective study of the impact on clinical outcomes and mortality rate. *Infection and Drug Resistance*, Volume 12:493–499.

Awdishu, L., Connor, A., Bouchard, J., Macedo, E., Chertow, G., Mehta, R. 2018. Use of Estimating Equations for Dosing Antimicrobials in Patients with Acute Kidney Injury Not Receiving Renal Replacement Therapy. *Journal of Clinical Medicine*, 7(8):211–211.

Blanco, V., Hernandorena, C., Sciobona, P., Belloso, W., Musso, C. 2019. Acute Kidney Injury Pharmacokinetic Changes and Its Impact on Drug Prescription. *Healthcare*, 7(1):10–10.

Bouchard, J., Macedo, E., Soroko, S., Chertow, G. M., Himmelfarb, J., Ikizler, T. A., Paganini, E. P., Mehta, R. L. 2010. Comparison of methods for estimating glomerular filtration rate in critically ill patients with acute kidney injury. *Nephrology Dialysis Transplantation*, 25(1):102–107.

Brater, D. C. 1983. Drug use in renal disease. Sydney: Adis Health Science Press.

Chertow, G. M., Burdick, E., Honour, M., Bonventre, J. V., Bates, D. W. 2005. Acute Kidney Injury, Mortality, Length of Stay, and Costs in Hospitalized Patients. *Journal of the American Society of Nephrology*, 16(11):3365–3370.

Chertow, G. M., Levy, E. M., Hammermeister, K. E., Grover, F., Daley, J. 1998. Independent Association between Acute Renal Failure and Mortality following Cardiac Surgery. *The American Journal of Medicine*, 104(4):343–348.

Chiou, W. L., Hsu, F. H. 1975. A new simple and rapid
method to monitor the renal function based on pharmacokinetic consideration of endogeneous creatinine. *Res Commun Chem Pathol Pharmacol*, 10(2):315–330.

Cockcroft, D. W., Gault, M. H. 1976. Prediction of Creatinine Clearance from Serum Creatinine. *Nephron*, 16(1):31–41.

Dager, W., Halilovic, J. 2014. Acute kidney injury. *Pharmacotherapy: A Pathophysiologic Approach*, pages 1409–1458.

Dowling, T. C., Matzke, G. R., Murphy, J. E., Burkart, G. J. 2010. Evaluation of Renal Drug Dosing: Prescribing Information and Clinical Pharmacist Approaches. *Pharmacotherapy*, 30(8):776–786.

Giles, P. D., Fitzmaurice, D. A. 2007. Formula estimation of glomerular filtration rate: have we gone wrong? *BMJ*, 334(7605):1198–1200.

Golik, M. V., Lawrence, K. R. 2008. Comparison of Dosing Recommendations for Antimicrobial Drugs Based on Two Methods for Assessing Kidney Function: Cockcroft-Gault and Modification of Diet in Renal Disease. *Pharmacotherapy*, 28(9):1125–1132.

Hermsen, E. D., Maiefski, M., Florescu, M. C., Qiu, F., Rupp, M. E. 2009. Comparison of the Modification of Diet in Renal Disease and Cockcroft-Gault Equations for Dosing Antimicrobials. *Pharmacotherapy*, 29(6):649–655.

Israni, A. K., Kasiske, B. L. 2007. Laboratory assessment of kidney disease: clearance, urinalysis, and kidney biopsy. *Brenner and Rector’s: The Kidney*, pages 724–756.

Jelliffe, R. W., Jelliffe, S. M. 1972. A computer program for estimation of creatinine clearance from unstable serum creatinine levels, age, sex, and weight. *Mathematical Biosciences*, 14(1-2):17–24.

Langlois, V. 2008. Laboratory Evaluation at Different Ages. *Comprehensive Pediatric Nephrology*, pages 39–54.

Mehta, R. L., Pascual, M. T., Soroko, S., Savage, B. R., Himmelfarb, J., Ikizler, T. A., Paganini, E. P., Cherlow, G. M. 2004. Spectrum of acute renal failure in the intensive care unit: The PICARD experience. *Kidney International*, 66(4):1613–1621.

Nguyen, M. T., Maynard, S. E., Kimmel, P. L. 2009. Misapplications of Commonly Used Kidney Equations: Renal Physiology in Practice. *Clinical Journal of the American Society of Nephrology*, 4(3):528–534.

Nyman, H. A., Dowling, T. C., Hudson, J. Q., Peter, W. L. S., Joy, M. S., Nolin, T. D. 2011. Comparative Evaluation of the Cockcroft-Gault Equation and the Modification of Diet in Renal Disease (MDRD) Study Equation for Drug Dosing: An Opinion of the Nephrology Practice and Research Network of the American College of Clinical Pharmacy. *Pharmacotherapy*, 31(11):1130–1144.

O’Connell, M. B., Dwinell, A. M., Bannick-Mohrland, S. D. 1992. Predictive Performance of Equations to Estimate Creatinine Clearance in Hospitalized Elderly Patients. *Annals of Pharmacotherapy*, 26(5):627–635.

Peyrière, H., Branger, B., Bengler, C., Vécina, F., Piziani, V., Hillaire-Buys, D., Blayac, J. P. 2001. Neurologic toxicity caused by zelitrex (valaciclovir) in 3 patients with renal failure. Is overdose associated with improvement of product bioavailability improvement? *La Revue de Medecine Interne*, 22(3):297–303.

Pirmohamed, M., Park, B. K. 2003. Adverse drug reactions: back to the future. *British Journal of Clinical Pharmacology*, 55(5):486–492.

Smythe, M., Hoffman, J., Kizy, K., Dmuchowski, C. 1994. Estimating creatinine clearance in elderly patients with low serum creatinine concentrations. *American Journal of Hospital Pharmacy*, 51(2):198–204.

Uchino, S., Kellum, J. A., Bellomo, R., Doig, G. S., Morimatsu, H., Morgera, S., Schetz, M., Tan, L., Bouman, C., Macedo, E., Gibney, N., Tolwani, A., Ronco, C. 2005. Acute Renal Failure in Critically Ill Patients: a multinational, multicenter study. *JAMA*, 294(7):813–818.

Wargo, K. A., Eiland, E. H., Hamm, W., English, T. M., Phillippe, H. M. 2006. Comparison of the Modification of Diet in Renal Disease and Cockcroft–Gault Equations for Antimicrobial Dosage Adjustments. *Annals of Pharmacotherapy*, 40(7-8):1248–1253.

Zaltzman, J. S., Whiteside, C., Cattran, D. C., Lopez, F. M., Logan, A. G. 1996. Accurate measurement of impaired glomerular filtration using single-dose oral cimetidine. *American Journal of Kidney Diseases*, 27(4):504–511.